Uncategorised

In this edition of Clinical Chronicles, you’ll find updates on our focus on quality throughout the organisation, celebrate positive outcomes from recent studies, and we share some big news for Christchurch!

In this edition of Clinical Chronicles, you’ll find updates on our focus on quality throughout the organisation, celebrate positive outcomes from recent studies, and we share changes implemented that you have asked for.

NZCR's commitment to rigorous research and patient safety is reflected in the positive results emerging from several key studies. Here's a look at recent successes that underscore NZCR's dedication to advancing global health. 

A drug involved in the FLAMINGO Auckland study has received Orphan Drug Designation from the FDA for the treatment of Cystic Fibrosis. This is a major step forward in the journey to develop new treatments for this challenging genetic condition.

Professor Gane’s presence at APASL 2025 served as a powerful reminder of NZCR’s status as a world-class clinical research organisation.

Selarsdi, a biosimilar drug recently tested at NZCR for psoriasis and active psoriatic arthritis, has been granted approval for sale in 83 countries, including NZ. Thanks to all our participants for helping make this drug a reality, enabling access to millions more people worldwide. 

In medical research, especially in medical trials like those carried out by NZCR, it's important that people fully understand what a clinical trial involves, as well as the risks and benefits. So, before someone joins a clinical trial, NZCR must give potential participants all the details about the study.

NZCR was recently involved in promising Phase-1 research of a new drug, TLC-2716, to treat people with severe high triglycerides and NASH. These promising early results, enables OrsoBio to move on to Phase-2a stage of testing with patients who have high triglycerides and liver fat.

Clinical trials are an incredibly important part of the process to bring new drugs to market and a participant’s safety is the number one priority in any clinical study.  Read about the safety protocols and checks completed throughout the trial process.